Active agent having the potential for use in the treatment of alzheimer's and certain neurodegenerative disorders
A novel compound enhances hCA enzyme activity to treat Alzheimer's and neurodegenerative disorders, addressing the limitations of existing treatments by providing an alternative mechanism beyond acetylcholinesterase inhibition.
WO2026142673A1PCT designated stage Publication Date: 2026-07-02T C ANKARA UNIVERSITESI REKTORLUGU +2
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- T C ANKARA UNIVERSITESI REKTORLUGU
- Filing Date
- 2025-12-24
- Publication Date
- 2026-07-02
AI Technical Summary
Technical Problem
Existing treatments for Alzheimer's disease primarily target acetylcholinesterase enzymes, leading to significant side effects, and there is a need for new molecules that can increase the activity of hCA enzymes to treat Alzheimer's and neurodegenerative disorders through different mechanisms.
Method used
Development of a compound, Mono-ferrocenyl-spiro(N/O)-trispiro(N/O)-cyclotetraphosphazene, which acts as an activator for hCA enzymes, enhancing their activity to treat Alzheimer's and certain neurodegenerative disorders.
Benefits of technology
The compound effectively increases the activity of hCA enzymes, improving cognitive functions and alleviating symptoms of Alzheimer's with minimal side effects by utilizing a novel mechanism of action.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure IMGF000003_0001 
Figure IMGF000004_0001 
Figure IMGF000005_0001
Abstract
The invention relates to an active agent increasing the activity of α-carbonic anhydrase (hCA) enzymes, having the potential for use in the treatment of Alzheimer's and certain neurodegenerative disorders.
Need to check novelty before this filing date? Find Prior Art